ArticleClinical & experimental metastasis2009
Multiple forms of BRMS1 are differentially expressed in the MCF10 isogenic breast cancer progression model.
Article in Clinical & experimental metastasis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Pooled it
- Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells.BMC cancer · 2019Article
- Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.The Journal of pathology · 2016Article
- Increased autophagic response in a population of metastatic breast cancer cells.Oncology letters · 2016Article
- Expression of the metastasis suppressor BRMS1 in uveal melanoma.Ecancermedicalscience · 2014Article
- Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.PloS one · 2014Article
- Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells.Molecular cancer research : MCR · 2013Article
- Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors.Oncogene · 2013Article
- Mitochondrial bioenergetics of metastatic breast cancer cells in response to dynamic changes in oxygen tension: effects of HIF-1α.PloS one · 2013Article
- Article
- Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival.BMC cancer · 2012Article
- Location, location, location: the BRMS1 protein and melanoma progression.BMC medicine · 2012Review
- Metastasis-associated protein 1 drives tumor cell migration and invasion through transcriptional repression of RING finger protein 144A.The Journal of biological chemistry · 2012Article
- Review
- 2D difference gel electrophoresis analysis of different time points during the course of neoplastic transformation of human mammary epithelial cells.Journal of proteome research · 2011Article
- Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer.Molecules and cells · 2011Article
- Metastasis suppressor genes at the interface between the environment and tumor cell growth.International review of cell and molecular biology · 2011Review
- Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression.International journal of cancer · 2009Article
- A shift from nuclear to cytoplasmic breast cancer metastasis suppressor 1 expression is associated with highly proliferative estrogen receptor-negative breast cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Clinical studies evaluating the mRNA expression level of the BRMS1 metastasis suppressor in the progression of breast cancer have not been consistent. The purpose of this study was to characterize endogenous BRMS1 mRNA and protein in a model of the progression of breast cancer. BRMS1 protein expression was evaluated in the genetically related MCF10 cell lines representing 'normal' breast epithelial cells (MCF10A), pre-malignant breast disease (MCF10AT), comedo ductal carcinoma in situ (MCF10DCIS.com), and metastatic carcinoma (MCF10CAa.1 and MCF10CAd.1alpha) with two antibodies that recognize distinct epitopes in the BRMS1 protein. Nuclear expression of the characteristic *35 kDa BRMS1 protein was detected in all cell lines. Because BRMS1 was expressed in the metastatic MCF10 variants, the BRMS1 exons were sequenced to scan for possible genetic mutations. BRMS1 was wild-type with the exception of a synonymous T/C transition in exon 7. However, alternatively spliced variants were detected by RT-PCR. Two variants, BRMS1.v2 and BRMS1.v4 were only detected in the MCF10A and AT cell lines, while BRMS1 and BRMS1.v3 were detected in all lines. These results demonstrate that expression of the characteristic *35 kDa BRMS1 protein is not sufficient to prevent metastasis. The differential expression of alternative splice variants suggests caution should be taken when evaluating BRMS1 mRNA in clinical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.